Phase Ib/II Study of Sulfatinib in Treating Advanced Neuroendocrine Tumors
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Jing Li, MD
Hutchison Medi Pharma
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
7 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Beijing Cancer Hospital
Beijing, Beijing Municipality, China
- Peking Union Medical College Hospital
Beijing, Beijing Municipality, China
- the 307 Hospital of People'S Liberation Army
Beijing, Beijing Municipality, China
- Sun Yat-Sen University Cancer Center
Guangzhou, Guangdong, China
- Shanghai Pulmonary Hospital
Shanghai, Shanghai Municipality, China
- West China Hospital, Sichuan University
Chengdu, Sichuan, China
- the First Affiliated Hospital, Zhejiang University
Hangzhou, Zhejiang, China
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Oct 2014
- Primary completion
- 23 Aug 2017
- Completion
- 23 Aug 2017
- Last update posted
- 13 Nov 2018
- Registered enrollment
- 81
- Registry id
- NCT02267967
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.